- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.07. | UK biotechs struggling to access finance as scale-up concerns grow | ||
| 06.07. | Novartis to acquire Myricx Bio in up to $1.5bn deal | ||
| 06.07. | Roche pens $490m Astex breast cancer license deal | ||
| 06.07. | Besins Healthcare boosts drug delivery portfolio with UniD deal | ||
| 03.07. | WHO intensifies Ebola-curbing efforts through drug trial and diagnostic rollout | ||
| 03.07. | US-UK pharma trade deal paints a costly economic picture for NHS | ||
| 03.07. | SK bioscience to lead Gates Foundation-funded ROTOR project | ||
| 03.07. | European Commission approves Novartis' Itvisma to treat SMA | ||
| 02.07. | Ipsen bolsters rare disease pipeline in €700m Memo takeover | ||
| 02.07. | FDA widens Vertex's Casgevy use for paediatric patients | ||
| 02.07. | Insilico Medicine, Takeda partner on AI-driven drug discovery | ||
| 02.07. | Inocras, AimedBio team up for cancer treatments | ||
| 01.07. | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | ||
| 01.07. | Sanofi aims for Nexviazyme approval in younger Pompe disease patients | ||
| 01.07. | Anthropic debuts AI-driven pharma R&D tool, Claude Science | ||
| 01.07. | Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown | ||
| 01.07. | US FDA rejects approval of Unicycive's kidney disease therapy | ||
| 01.07. | Eli Lilly and Innovent agree Verzenios commercialisation deal in China | ||
| 30.06. | Lilly and Regeneron amongst first incumbents to FDA's fast-track facility scheme | ||
| 30.06. | Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger | ||
| 30.06. | Anixa Biosciences secures Korean patent for breast cancer vaccine | ||
| 30.06. | Zymeworks agrees to buy Theravance Biopharma for $929m | ||
| 29.06. | EMA backs market rollback of rare disease drug Tavneos over data concerns | ||
| 29.06. | Biogen trims Apellis pipeline and R&D team after $5.6bn takeover | ||
| 29.06. | FDA issues complete response letter to Sobi's NASP for gout |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.